Physician

Alexandra Shingina, MD

According to 2025 Medicare claims, Alexandra Shingina, MD (NPI: 1952825796) practices gastroenterology in the Detroit-Dearborn-Livonia, MI market, with the plurality of this provider's patient population coming from Wayne, MI. This provider's primary affiliated billing organization is REGENTS OF THE UNIVERSITY OF MICHIGAN (NPI: 1801827639; TIN: 386006309) and primary practice location at 48109-5000. Shingina is affiliated with the POM ACO (ACO ID: A1297), Connected Care of Middle Tennessee, LLC (ACO ID: A3840), AdvantagePoint Health Alliance - Great Lakes, LLC (ACO ID: A4652), and Honest MSSP of Michigan LLC (ACO ID: A5616), participating under the MSSP model.

Shingina's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 155 traditional Medicare patients, billed 194 HCPCS/CPT codes, and received $19,418 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 437 prescription claims across 138 beneficiaries totaling $266,776 in drug costs, led by Xifaxan (Rifaximin). DME data shows 98 claims. Open Payments data shows 2 records totaling $2,801. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	204	489	$34,563
2020	265	622	$45,993
2021	210	406	$30,556
2022	239	457	$34,120
2023	196	333	$29,021
2024	155	194	$19,418

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	11	$167
2019	46	137	$195,839
2020	138	590	$682,980
2021	156	811	$466,627
2022	150	635	$510,236
2023	125	450	$335,238
2024	138	437	$266,776

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	76	339	$11,830
2021	91	686	$21,599
2022	61	345	$7,295
2023	N/R	56	$769
2024	30	98	$1,740

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	19	19	$112
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	57	58	$96
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	12	25	$89
43235	Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope	12	12	$67

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xifaxan	Rifaximin	72	2,090	$219,603
Ursodiol	Ursodiol	25	1,830	$6,291
Tacrolimus	Tacrolimus	35	2,407	$4,834
Lactulose	Lactulose	26	1,095	$1,927
Mycophenolate Mofetil	Mycophenolate Mofetil	17	794	$703

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	14	46	$948
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	16	40	$641
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	0	$0	N/R
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$2,801	Gilead Sciences, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alexandra Shingina, MD?

Tedicare shows public-source Medicare data for Alexandra Shingina, MD (NPI 1952825796), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alexandra Shingina, MD have ACO affiliation data?

Alexandra Shingina, MD is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297), Connected Care of Middle Tennessee, LLC (MSSP, ACO ID A3840), AdvantagePoint Health Alliance - Great Lakes, LLC (MSSP, ACO ID A4652), and Honest MSSP of Michigan LLC (MSSP, ACO ID A5616).

What billing organization is linked to Alexandra Shingina, MD?

Alexandra Shingina, MD is linked to REGENTS OF THE UNIVERSITY OF MICHIGAN (billing NPI 1801827639) in the available physician profile data.

Does Alexandra Shingina, MD have Open Payments data?

Alexandra Shingina, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.